# Hirsutism

Evaluate hirsutism by tempo, virilization, menstrual pattern, and objective androgen testing. Most cases reflect PCOS or idiopathic hyperandrogenism, but rapid progression, later onset, or marked biochemical androgen excess requires urgent exclusion of adrenal or ovarian neoplasia.

**Clinical question:** How should clinicians distinguish common hirsutism from tumor-associated androgen excess and select symptom-directed treatment?

Updated: 2026-09-16T00:21:13.380278+00:00

## What matters in practice
- Document onset, rate of progression, menstrual history, acne, alopecia, and virilization; later onset or rapid progression shifts concern from PCOS toward neoplastic androgen excess. [6]
- Use modified Ferriman-Gallwey scoring to document terminal-hair burden; in otherwise mild disease without red flags, total testosterone plus SHBG can support calculation of a free androgen index. [1]
- Obtain 17-hydroxyprogesterone when testosterone is elevated or the phenotype suggests nonclassic congenital adrenal hyperplasia; a basal morning follicular-phase value above 5 l/L should prompt stimulation testing. [1][6]
- Urgently refer patients with suspected androgen-secreting neoplasia to an experienced center rather than treating presumptively as PCOS. [6]
- For distressing hirsutism, combine patient-selected hair removal with hormonal suppression when appropriate; spironolactone may be added for more severe disease, with closer adverse-effect monitoring. [18]

## Identify hirsutism that needs expedited evaluation

Tempo and virilization determine whether routine outpatient testing is appropriate.

At the first visit, establish age at onset, duration, rate of change, menstrual frequency, acne, female-pattern hair loss, and symptoms or signs of virilization. Assess BMI and blood pressure, and document whether symptoms are distressing enough to warrant treatment. Early-onset, slowly progressive mild androgen-excess features are more compatible with PCOS; late-onset or rapidly progressive virilizing symptoms are more concerning for an androgen-producing tumor. [5][6]

Actively look for syndrome-specific clues that redirect testing: Cushing syndrome features, severe insulin resistance, genital ambiguity, and findings of congenital adrenal hyperplasia. Genital ambiguity points toward virilizing forms of congenital adrenal hyperplasia; classic CAH may also present with hirsutism when glucocorticoid replacement is inadequate. [6][20][21]

If neoplastic androgen excess is suspected on the basis of rapid progression, virilization, or concerning clinical context, make an urgent referral to a center with relevant endocrine and gynecologic expertise. Do not delay escalation by assuming PCOS solely because hirsutism and menstrual irregularity coexist. [6][7]
- Record the modified Ferriman-Gallwey score across nine androgen-sensitive sites: upper lip, chin, chest, upper arms, upper and lower back, upper and lower abdomen, and thighs. [1]
- Treat acne, hirsutism, and androgenic alopecia as a hyperandrogenism cluster rather than as isolated dermatologic findings when menstrual irregularity or biochemical androgen elevation is present. [5][11]
- In adolescents, include physiologic pubertal hyperandrogenism, idiopathic hyperandrogenism, and PCOS in the initial differential; longitudinal assessment may be necessary before assigning PCOS. [5]

*Clinical patterns that change the urgency and diagnostic branch. [5][6][20][21]*

| Pattern | Most informative discriminator | Immediate next step |
| --- | --- | --- |
| Mild, slowly progressive hirsutism beginning near puberty | Menstrual history plus androgen assessment; phenotype is commonly compatible with PCOS or idiopathic hyperandrogenism. [5][6] | Perform targeted biochemical evaluation when clinically indicated and address distressing hair growth. [1][5] |
| Rapid progression, later onset, or virilizing features | Clinical tempo and virilization predict non-PCOS pathology, including androgen-producing tumor. [6] | Urgently refer for expert evaluation of neoplastic androgen excess. [6] |
| Elevated testosterone or phenotype suggestive of adrenal enzyme defect | 17-hydroxyprogesterone pattern distinguishes possible nonclassic CAH from more common causes. [1][6] | Obtain morning follicular-phase 17-hydroxyprogesterone and proceed to stimulation testing if elevated. [6] |
| Genital ambiguity or known classic CAH | Suggests virilizing congenital adrenal hyperplasia or inadequate glucocorticoid replacement. [20][21] | Assess CAH-directed endocrine management rather than classifying the presentation as isolated PCOS. [21] |

## Select androgen testing by severity and phenotype

Avoid indiscriminate panels in isolated low-burden hair growth, but do not miss biochemical hyperandrogenism.

Use the clinical examination and modified Ferriman-Gallwey score to determine testing intensity. In isolated hair growth or a low modified Ferriman-Gallwey score, biochemical testing is usually unnecessary. For the common mild presentation without red flags, measure testosterone and SHBG and calculate the free androgen index using the local laboratory reference range; there is no universally accepted normal free androgen index cutoff. [1]

In adolescents with clinical hyperandrogenism, guidelines commonly include total testosterone, free testosterone, or both. A total or free testosterone concentration above adult female normative values supports biochemical hyperandrogenism; interpretation must use the reporting laboratory's adult female reference interval. [5]

Use a broader androgen panel—17-hydroxyprogesterone, androstenedione, DHEAS, and testosterone—when red flags suggest marked androgen excess, an adrenal process, or another endocrinopathy. This approach is more appropriate than pelvic ultrasonography as the initial universal test for an adolescent presenting with hirsutism. [1][2]
- Measure 17-hydroxyprogesterone in patients with elevated testosterone or clinical features suggesting nonclassic congenital adrenal hyperplasia. [1]
- Obtain basal 17-hydroxyprogesterone in the morning during the follicular phase when possible. A value above 5 l/L should be followed by stimulation testing; a stimulated value above 30 l/L is diagnostic for nonclassic congenital adrenal hyperplasia in the cited guideline. [6]
- Use local assay-specific and laboratory-specific cutoffs for testosterone, SHBG-derived free androgen index, and other androgen results. [1][5]

### Interpretation that changes the branch

An elevated 17-hydroxyprogesterone redirects evaluation toward nonclassic congenital adrenal hyperplasia, which can resemble PCOS through menstrual irregularity, hirsutism, and acne. Nonclassic CAH usually has an insidious course beginning around puberty, whereas overt virilization is unusual; this contrasts with the rapid virilization that should heighten concern for an androgen-secreting tumor. [6][9]
- A testosterone elevation does not establish PCOS by itself; use symptom tempo, menstrual history, examination for Cushing syndrome or severe insulin resistance, and 17-hydroxyprogesterone testing to exclude alternate etiologies. [6][7]
- Do not use pelvic ultrasound alone to exclude adrenal disease, nonclassic CAH, or androgen-secreting neoplasia. [1][2]

*Targeted biochemical testing for hirsutism. [1][5][6]*

| Clinical setting | Test and timing | Result interpretation and next action |
| --- | --- | --- |
| Isolated low-burden hair growth without red flags | Usually no biochemical testing. [1] | Provide symptom-directed management if hair growth is distressing. [5][18] |
| Mild hirsutism without red flags | Total testosterone and SHBG; calculate free androgen index using local cutoffs. [1] | Interpret against laboratory standards; expand evaluation if testosterone is elevated or phenotype changes. [1] |
| Clinical hyperandrogenism in an adolescent | Total testosterone, free testosterone, or both; screen with 17-hydroxyprogesterone. [5] | Values above adult female norms support biochemical hyperandrogenism; evaluate alternate causes before labeling PCOS. [5] |
| Elevated testosterone or suspected nonclassic CAH | Morning follicular-phase basal 17-hydroxyprogesterone. [1][6] | More than 5 l/L: proceed to stimulation testing; stimulated value more than 30 l/L is diagnostic in the cited guideline. [6] |
| Rapid progression or virilization | Androgen testing directed by an expert center. [6] | Urgently evaluate for androgen-producing neoplasia rather than managing as routine PCOS. [6] |

## Separate PCOS, nonclassic CAH, and neoplastic androgen excess

Clinical pattern plus targeted hormones should determine the next referral and treatment pathway.

PCOS is the most common hyperandrogenic disorder associated with hirsutism. A pattern of hirsutism with acne, androgenic alopecia, and menstrual irregularity supports hyperandrogenism, but secondary causes relevant to a PCOS-like presentation include hypothyroidism, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, adrenal or ovarian neoplasms, Cushing syndrome, and acromegaly. [4][7][11]

Nonclassic congenital adrenal hyperplasia should be considered particularly when symptoms are insidious from puberty and 17-hydroxyprogesterone is elevated. Basal morning follicular-phase 17-hydroxyprogesterone greater than 5 l/L warrants stimulation testing; a stimulated concentration greater than 30 l/L is diagnostic in the cited clinical guideline. [6]

Androgen-secreting tumors are uncommon but clinically consequential. Older age, late onset, rapid progression, and virilization are the most useful bedside triggers for urgent specialty assessment. In postmenopausal patients, androgen excess may originate in the ovary or adrenal gland, so the diagnostic strategy should not presume a single source. [6][12][22]
- Consider Cushing syndrome and severe insulin resistance when their syndrome-specific physical features accompany androgen excess. [6]
- If classic CAH is already diagnosed, reassess adequacy of glucocorticoid replacement when hirsutism worsens. [21]
- Use the patient's degree of symptom burden to decide whether to initiate cosmetic or pharmacologic treatment; biochemical abnormalities alone do not establish a need for symptom treatment. [5]

*Etiologic pattern recognition in hirsutism. [4][6][7][12][22]*

| Etiologic branch | Clues favoring the diagnosis | Decisive next action |
| --- | --- | --- |
| PCOS or idiopathic hyperandrogenism | Early, gradual hirsutism; acne, alopecia, or menstrual irregularity may coexist. [5][6][11] | Assess biochemical hyperandrogenism as indicated, exclude key secondary causes, and treat symptoms that distress the patient. [5][7] |
| Nonclassic congenital adrenal hyperplasia | Insidious onset around puberty; increased 17-hydroxyprogesterone. [6] | Use morning follicular-phase 17-hydroxyprogesterone and stimulation testing when basal value exceeds 5 l/L. [6] |
| Adrenal or ovarian androgen-secreting neoplasia | Late onset, rapid progression, or virilization. [6][12][22] | Urgent referral to an experienced center for source-directed evaluation. [6] |
| Other endocrinopathy | Cushing syndrome features, severe insulin resistance, or findings suggestive of hypothyroidism, hyperprolactinemia, or acromegaly. [6][7] | Order syndrome-directed testing rather than repeating only androgen assays. [6][7] |

## Treat distressing hair growth while etiologic evaluation proceeds

Management should reflect patient priorities, pregnancy potential, disease severity, and the underlying endocrine diagnosis.

Determine whether treatment is wanted before prescribing medication: in adolescents with hyperandrogenic symptoms, therapy is indicated when acne or hirsutism is distressing to the patient. Pair medical treatment with a hair-removal method selected by the patient, including electrolysis or laser hair removal; eflornithine hydrochloride 13.9% topical cream may help reduce unwanted facial hair. [5][18]

Oral contraceptive therapy is a longstanding hormonal-suppression option for menstrual irregularity and hirsutism in PCOS, acting in part through suppression of ovarian androgen production. For more severe hirsutism, spironolactone can be added to oral-contraceptive therapy, with closer monitoring for adverse effects than with other options. [16][17][18]

Antiandrogens are effective for hirsutism, but selection requires attention to pregnancy risk and contraindications. Spironolactone 100 mg/day has been reported to be more effective than finasteride 5 mg/day for hyperandrogenic hirsutism. Spironolactone is contraindicated in pregnancy, and potassium monitoring is particularly relevant in patients with kidney disease or excessive potassium intake. [15][19][23]
- Use mechanical or procedural hair reduction concurrently with endocrine treatment when the patient wants a more immediate cosmetic effect; endocrine therapy does not remove existing terminal hairs. Electrolysis and laser hair removal are established options. [18]
- Avoid spironolactone when pregnancy is possible without reliable pregnancy prevention because of pregnancy contraindication. [19]
- For known CAH, direct treatment toward adequate glucocorticoid replacement rather than escalating cosmetic therapy alone. [21]

### Medication selection and follow-up

When choosing spironolactone, review renal disease, dietary potassium exposure, concurrent potassium-raising drugs, and pregnancy status before initiation. The cited evidence specifically identifies kidney disease and excessive potassium intake as settings in which potassium monitoring is relevant. [19]
- Spironolactone: 100 mg/day was more effective than finasteride 5 mg/day in the cited comparison for hyperandrogenic hirsutism. [15]
- Topical eflornithine: 13.9% cream may be used for unwanted facial hair as an adjunct to hair-removal approaches. [18]
- Escalate or redirect therapy when the clinical course becomes rapid, virilizing, or discordant with the presumed diagnosis; repeat etiologic assessment rather than simply adding antiandrogen therapy. [6]

*Symptom-directed treatment options for hirsutism. [15][16][17][18][19][23]*

| Option | Best use | Key limitation or monitoring |
| --- | --- | --- |
| Laser hair removal or electrolysis | Patient-desired direct reduction of unwanted terminal hair. [18] | Does not replace evaluation for clinically significant androgen excess. [6][18] |
| Eflornithine hydrochloride 13.9% topical cream | Adjunct for unwanted facial hair. [18] | Use as symptom management; evaluate systemic hyperandrogenism when indicated. [18] |
| Oral contraceptive therapy | Hormonal suppression for PCOS-associated menstrual irregularity and hirsutism. [16][17] | Select according to usual contraceptive safety assessment and patient goals; the cited literature describes ovarian androgen suppression. [17] |
| Spironolactone | More severe hirsutism, often added to oral-contraceptive therapy. [18] | Contraindicated in pregnancy; consider potassium monitoring with kidney disease or excessive potassium intake. [19] |
| Finasteride | Antiandrogen alternative; studied at 5 mg/day in a comparison with spironolactone. [15] | Spironolactone 100 mg/day was more effective in that cited comparison. [15] |

## Modify the diagnostic threshold in adolescents and postmenopausal patients

Age and reproductive stage change the pretest probability and interpretation of persistent androgen excess.

In adolescents, physiologic pubertal hyperandrogenism, idiopathic hyperandrogenism, and PCOS can overlap clinically. Obtain total testosterone, free testosterone, or both when biochemical confirmation is needed, screen for nonclassic CAH with 17-hydroxyprogesterone, and use longitudinal evaluation when PCOS remains uncertain. Do not withhold symptomatic treatment solely because diagnostic labeling is still evolving. [5]

In postmenopausal patients, new androgen excess deserves a lower threshold for source-directed evaluation because ovarian and adrenal etiologies both occur and adrenal androgen-secreting adenomas, although exceptionally rare, have been reported. Document the modified Ferriman-Gallwey score and prioritize the tempo of new or worsening virilization. [12][22][24]
- For adolescents, assess BMI, blood pressure, acne, hirsutism, alopecia, and menstrual pattern at baseline and over follow-up. [5]
- For postmenopausal patients with new or rapidly progressive features, do not extrapolate a typical reproductive-age PCOS pattern without reassessing for adrenal or ovarian androgen excess. [12][22]

*Age-specific decisions in hirsutism evaluation. [5][12][22][24]*

| Population | Interpretive issue | Action |
| --- | --- | --- |
| Adolescent | Pubertal physiology, idiopathic hyperandrogenism, and evolving PCOS may overlap. [5] | Measure testosterone as indicated, screen for nonclassic CAH with 17-hydroxyprogesterone, and follow longitudinally when PCOS remains uncertain. [5] |
| Premenopausal adult | PCOS is the most common hyperandrogenic disorder associated with hirsutism. [4] | Use tempo, menstrual pattern, androgen testing, and 17-hydroxyprogesterone to distinguish PCOS from secondary causes. [1][6][7] |
| Postmenopausal patient | Ovarian and adrenal sources of androgen excess must both be considered. [22] | Expedite evaluation for new, progressive, or virilizing androgen excess. [6][12][22] |

## References
1. Fifteen-minute consultation: Approach to the adolescent presenting with hirsutism | ADC Education & Practice Edition — ep.bmj.com — https://ep.bmj.com/content/109/2/66
2. Approach to the adolescent presenting with hirsutism — ep.bmj.com — https://ep.bmj.com/content/edpract/109/2/66.full.pdf
3. CLINICAL REVIEW Management of hirsutism - The BMJ — www.bmj.com — https://www.bmj.com/content/bmj/338/7698/Clinical_Review.full.pdf
4. Evaluation and Treatment of Hirsutism in Premenopausal ... — academic.oup.com — https://academic.oup.com/jcem/article/103/4/1233/4924418
5. Screening and Management of the Hyperandrogenic Adolescent — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000003475~screening-and-management-of-the-hyperandrogenic-adolescent
6. Society for Endocrinology Clinical Practice Guideline for the ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.15265
7. Prevalence of Congenital Adrenal Hyperplasia in... : Indian Journal of Endocrinology and Metabolism — journals.lww.com — https://journals.lww.com/indjem/fulltext/2026/05000/prevalence_of_congenital_adrenal_hyperplasia_in.9.aspx
8. Correlation of visual (modified Ferriman–Gallwey... : Philippine Journal of Obstetrics and Gynecology — journals.lww.com — https://journals.lww.com/pjog/fulltext/2025/01000/correlation_of_visual__modified_ferriman_gallwey.2.aspx
9. Non-Classical Congenital Adrenal Hyperplasia vs. Polycystic ... — academic.oup.com — https://academic.oup.com/jes/article/9/Supplement_1/bvaf149.2036/8297500
10. Approach to the Patient: Hirsutism - Oxford Academic — academic.oup.com — https://academic.oup.com/jcem/article/110/10/e3503/8108889
11. Approach to androgen excess in women: Clinical and biochemical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/cen.14710
12. Androgen-Secreting Adrenal Adenoma in a Postmenopausal ... — academic.oup.com — https://academic.oup.com/jcemcr/article/3/12/luaf250/8305614
13. Hirsutism : The Obstetrician & Gynaecologist - Ovid — journals.lww.com — https://journals.lww.com/01034179-202504000-00007
14. Dermatological care of gender‐diverse patients in Australia — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajd.14360
15. Medical treatment of hirsutism - Blume‐Peytavi - 2008 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2008.00215.x
16. Clinical management of PCOS - Tan - Obstetrics and Gynecology — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1034/j.1600-0412.2001.080008689.x
17. The long term health consequences of polycystic ovary syndrome — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2000.tb11644.x
18. Interventions for hirsutism (excluding laser and photoepilation therapy alone) - van Zuuren, EJ - 2015 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010334.pub2/full
19. [PDF] Metabolic and Neuro-Endocrine Effect of ... - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/61/NCT03981861/Prot_SAP_000.pdf
20. Approach to the Patient with Hirsutism - Oxford Academic — academic.oup.com — https://academic.oup.com/jcem/article/97/9/2957/2536701
21. Epidemiology, diagnosis and management of hirsutism: a ... — academic.oup.com — https://academic.oup.com/humupd/article/18/2/146/618266
22. Approach to Investigation of Hyperandrogenism in a ... — academic.oup.com — https://academic.oup.com/jcem/article/108/5/1243/6835644
23. Antiandrogens for the Treatment of Hirsutism: A Systematic ... — academic.oup.com — https://academic.oup.com/jcem/article/93/4/1153/2826183
24. investigation of postmenopausal androgen excess | The ... — academic.oup.com — https://academic.oup.com/jcem/article/111/9/2664/8698360

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.